keyword
MENU ▼
Read by QxMD icon Read
search

Pneumococcal vaccine in adults

keyword
https://www.readbyqxmd.com/read/29050992/the-impact-of-13-valent-pneumococcal-conjugate-vaccination-on-virus-associated-community-acquired-pneumonia-in-elderly
#1
Susanne M Huijts, Frank E J Coenjaerts, Marieke Bolkenbaas, Cornelis H van Werkhoven, Diederick E Grobbee, Marc J M Bonten
OBJECTIVES: Our objective was to evaluate whether vaccination with the 13-valent pneumococcal conjugate vaccine (PCV13) prevents the incidence of community-acquired pneumonia (CAP) caused by influenza (Influenza-Associated CAP, IA-CAP) or other respiratory viruses in elderly. METHODS: This analysis was part of the Community-Acquired Pneumonia immunization Trial in Adults (CAPiTA); a double blind, randomized, placebo-controlled trial in 84,496 immunocompetent individuals aged ≥65 years...
October 16, 2017: Clinical Microbiology and Infection
https://www.readbyqxmd.com/read/29031694/a-formative-research-guided-educational-intervention-to-improve-the-knowledge-and-attitudes-of-seniors-towards-influenza-and-pneumococcal-vaccinations
#2
Hanley J Ho, Yin Ying Chan, Muhamad Alif Bin Ibrahim, Anurupa A Wagle, Christina M Wong, Angela Chow
BACKGROUND: Adult influenza and pneumococcal vaccination rates in Singapore are low, and factors influencing knowledge and attitudes of seniors towards influenza, pneumonia and their respective vaccines are not well-known. Our study aims to understand the barriers and facilitators towards getting influenza and pneumococcal vaccinations among seniors in Singapore, and subsequently inform the conduct of a relevant community-based educational intervention, as well as evaluate the intervention outcomes...
October 11, 2017: Vaccine
https://www.readbyqxmd.com/read/29021946/predictors-of-pneumococcal-carriage-and-the-effect-of-the-13-valent-pneumococcal-conjugate-vaccination-in-the-western-australian-aboriginal-population
#3
Deirdre A Collins, Anke Hoskins, Thomas Snelling, Kalpani Senasinghe, Jacinta Bowman, Natalie A Stemberger, Amanda J Leach, Deborah Lehmann
BACKGROUND: The 7-valent pneumococcal conjugate vaccine (PCV7) was introduced to prevent invasive pneumococcal disease (IPD) in Western Australian (WA) Aboriginal people in 2001. PCV13 replaced PCV7 in July 2011, covering six additional pneumococcal serotypes; however, IPD rates remained high in Aboriginal people in WA. Upper respiratory tract pneumococcal carriage can precede IPD, and PCVs alter serotype distribution. METHODS: To assess the impact of PCV13 introduction, identify emerging serotypes, and assess risk factors for carriage, nasopharyngeal swabs and information on demographic characteristics, health, medication and living conditions from Aboriginal children and adults across WA from August 2008 to November 2014 were collected...
2017: Pneumonia
https://www.readbyqxmd.com/read/29020313/trends-in-invasive-pneumococcal-disease-ipd-in-cancer-patients-after-the-introduction-of-7-valent-pneumococcal-conjugate-vaccine-pcv7-a-20-year-longitudinal-study-at-a-major-urban-cancer-center
#4
Yeon Joo Lee, Yao-Ting Huang, Seong Jin Kim, Marina Kerpelev, Victoria Gonzalez, Anna Kaltsas, Genovefa Papanicolaou
Background: Rates of invasive pneumococcal disease (IPD) declined since routine childhood immunization with the 7-valent pneumococcal conjugate vaccine (PCV7) in 2000. We studied the impact of PCV7 on the incidence of IPD in cancer patients. Methods: This was a retrospective analysis of adult and pediatric patients treated at Memorial Sloan Kettering Cancer Center from 1992 to 2012. Recovery of Streptococcus pneumoniae from a sterile site defined IPD. IPD incidence was calculated as cases per 1,000 unique patient-visits per year (UPV)...
August 17, 2017: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
https://www.readbyqxmd.com/read/29020195/impact-of-pneumococcal-conjugate-vaccines-on-pneumonia-hospitalizations-in-high-and-low-income-subpopulations-in-brazil
#5
Joshua L Warren, Kayoko Shioda, Esra Kürüm, Cynthia Schuck-Paim, Roger Lustig, Robert J Taylor, Lone Simonsen, Daniel M Weinberger
Background: Pneumococcal conjugate vaccines (PCVs) are being used worldwide. A key question is whether the impact of PCVs on pneumonia is similar in low- and high-income populations. However, most low-income countries, where the burden of disease is greatest, lack reliable data that can be used to evaluate the impact. Data from middle-income countries that have both low- and high-income subpopulations can provide a proxy measure for the impact of the vaccine in low-income countries. Methods: We evaluated the impact of PCV10 on hospitalizations for all-cause pneumonia in Brazil, a middle-income country with localities that span a broad range of human development index (HDI) levels...
July 22, 2017: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
https://www.readbyqxmd.com/read/29017280/immunogenicity-of-the-13-valent-pneumococcal-conjugate-vaccine-in-older-adults-with-and-without-comorbidities-in-the-community-acquired-pneumonia-immunization-trial-in-adults-capita
#6
Anna M M van Deursen, Marlies A van Houten, Chris Webber, Michael Patton, Daniel A Scott, Scott Patterson, Mohinder Sidhu, Wayne Drews, William C Gruber, Emilio A Emini, Diederick E Grobbee, Marc J M Bonten, Elisabeth A M Sanders
Background: In the randomized controlled Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA), the efficacy of the 13-valent pneumococcal conjugate vaccine (PCV13) against first episodes of vaccine-type community-acquired pneumonia in adults aged ≥65 years was 46%. The long-term immunogenicity of PCV13 in pneumococcal vaccine-naive older adults was investigated as part of CAPiTA. Methods: We determined the immune responses to PCV13 before and at 1, 12, and 24 months after vaccination in 1006 PCV13 recipients and 1005 controls with 3 age-stratified study participant cohorts...
September 1, 2017: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
https://www.readbyqxmd.com/read/28988217/population-level-impact-of-infant-10-valent-pneumococcal-conjugate-vaccination-on-adult-pneumonia-hospitalisations-in-finland
#7
Omar Okasha, Hanna Rinta-Kokko, Arto A Palmu, Esa Ruokokoski, Jukka Jokinen, J Pekka Nuorti
INTRODUCTION: Limited data are available on population-level herd effects of infant 10-valent pneumococcal conjugate vaccine (PCV10) programmes on pneumonia. We assessed national trends in pneumococcal and all-cause pneumonia hospitalisations in adults aged ≥18 years, before and after infant PCV10 introduction in 2010. METHODS: Monthly hospitalisation rates of International Statistical Classification of Diseases, 10th revision (ICD-10)-coded primary discharge diagnoses compatible with pneumonia from 2004-2005 to 2014-2015 were calculated with population denominators from the population register...
October 7, 2017: Thorax
https://www.readbyqxmd.com/read/28987445/immunogenicity-and-safety-of-an-inactivated-quadrivalent-influenza-vaccine-co-administered-with-a-23-valent-pneumococcal-polysaccharide-vaccine-versus-separate-administration-in-adults-%C3%A2-50years-of-age-results-from-a-phase-iii-randomized-non-inferiority-trial
#8
Opokua Ofori-Anyinam, Geert Leroux-Roels, Mamadou Drame, Annelies Aerssens, Cathy Maes, Arshad Amanullah, Anne Schuind, Ping Li, Varsha K Jain, Bruce L Innis
INTRODUCTION: We compared co-administration versus separate administration of an inactivated quadrivalent influenza vaccine (IIV4) with a 23-valent pneumococcal polysaccharide vaccine (PPV23) in adults at high risk of complications of influenza and pneumococcal infection. METHODS: This phase III, placebo-controlled, observer-blind trial (NCT02218697) was conducted in France and Belgium during the 2014-2015 influenza season. Adults≥50years of age meeting their country's vaccination recommendations were randomized 1:1 to co-administration or separate administration...
October 5, 2017: Vaccine
https://www.readbyqxmd.com/read/28976399/-vaccination-in-the-elderly-population
#9
Z Lale Koldaş
It is known that the immune systems tend to weaken over time, putting elderly patients at higher risk for chronic diseases such as cardiovascular (CV) diseases, diabetes, chronic renal disorders and their complication as well as infectious disease leading to an increased mortality and morbidity rates in patients over 65 years old. Vaccination, a prophylactic treatment strategy, means that immunogenic materials from pathogens (or tumours) are administered to generate an adequate immune response specifically to these antigens...
September 2017: Türk Kardiyoloji Derneği Arşivi: Türk Kardiyoloji Derneğinin Yayın Organıdır
https://www.readbyqxmd.com/read/28964578/pneumococcal-vaccination-among-adults-with-work-related-asthma
#10
Katelynn E Dodd, Jacek M Mazurek
INTRODUCTION: Pneumococcal vaccination is recommended for all adults with asthma and a Healthy People 2020 goal aims to achieve 60% coverage among high-risk adults, including those with asthma. Adults with work-related asthma have more severe asthma symptoms than those with non-work-related asthma and are particularly vulnerable to pneumococcal pneumonia. METHODS: To assess pneumococcal vaccination coverage by work-related asthma status among ever-employed adults aged 18-64 years with current asthma, data from the 2012-2013 Behavioral Risk Factor Surveillance System Asthma Call-back Survey for ever-employed adults (18-64 years) with current asthma from 29 states were examined in 2016...
September 22, 2017: American Journal of Preventive Medicine
https://www.readbyqxmd.com/read/28955497/pneumococcal-vaccination-in-autoimmune-rheumatic-diseases
#11
REVIEW
Éva Rákóczi, Zoltan Szekanecz
Streptococcus pneumoniae is the leading cause of the community-acquired pneumonia. The mortality rate of invasive pneumococcal infections is high. Immunocompromised patients suffering from autoimmune inflammatory rheumatic diseases (AIRD) have a high risk for acquiring these infections. Protection against infection can be improved with vaccination. After using polysaccharide vaccines (PPV-23), in July 2013, a 13-valent conjugate vaccine (PCV-13) was approved for adults. Due to its conjugate form, this vaccine is the recommended choice in pneumococcal vaccine-naive patients...
2017: RMD Open
https://www.readbyqxmd.com/read/28951137/a-pharmacist-driven-academic-detailing-program-to-increase-adult-pneumococcal-vaccination
#12
Aisling R Caffrey, Jennifer M DeAngelis, Kristina E Ward, K Kelly Orr, Haley J Morrill, Michael Gosciminski, Kerry L LaPlante
OBJECTIVES: To describe our statewide, pharmacist-led education campaign to increase knowledge and awareness of pneumococcal immunization recommendations. SETTING: Immunization providers and residents in the state of Rhode Island. PRACTICE DESCRIPTION: A clinical pathway (i.e., decision-support tool) was developed to educate health professionals about appropriate indications, administration schedules, and frequently asked questions for the 2 different adult pneumococcal vaccines...
September 23, 2017: Journal of the American Pharmacists Association: JAPhA
https://www.readbyqxmd.com/read/28951105/epidemiology-of-invasive-pneumococcal-and-haemophilus-influenzae-diseases-in-northwestern-ontario-canada-2010-2015
#13
Vic Eton, Annette Schroeter, Len Kelly, Michael Kirlew, Raymond S W Tsang, Marina Ulanova
INTRODUCTION: North American Indigenous populations experience a high burden of invasive bacterial infections. Because Streptococcus pneumoniae and Haemophilus influenzae (Hi) have multiple antigenic variants, the existing vaccines cannot prevent all cases. This study addresses current epidemiology of invasive Hi and pneumococcal disease (IPD) in a region of Northwestern Ontario, Canada with a relatively high (82%) Indigenous population. METHODS: Data were retrieved from retrospective chart review at a hospital servicing a population of 29,000 (82% Indigenous), during January 2010-July 2015...
September 22, 2017: International Journal of Infectious Diseases: IJID
https://www.readbyqxmd.com/read/28941358/rates-of-vaccination-against-streptococcus-pneumoniae-in-cochlear-implant-patients
#14
Anna Piotrowska, Iwona Paradowska-Stankiewicz, Henryk Skarżyński
BACKGROUND Streptococcus pneumoniae can cause life-threatening illness, with invasive pneumococcal diseases (IPD) like meningitis, sepsis, bacteremic pneumonia, and bacteremia being major causes of morbidity and mortality. Studies have shown that patients who have had a cochlear implant, particularly children, have an increased risk of bacterial (pneumococcal) meningitis. Vaccination in patients with cochlear implants is important and recommended universally. The World Health Organization recommends the use of pneumococcal conjugate vaccines in all countries and considers their use to be a priority in all national immunization programs...
September 23, 2017: Medical Science Monitor: International Medical Journal of Experimental and Clinical Research
https://www.readbyqxmd.com/read/28929957/-serotype-distribution-and-antibiotic-resistance-of-streptococcus-pneumoniae-strains-isolated-from-the-adult-patients-in-a-turkish-%C3%A3-niversity-hospital
#15
Lütfiye Öksüz, Nezahat Gürler
Infections caused by Streptococcus pneumoniae are the most important cause of morbidity and mortality worldwide. S.pneumoniae is the most common cause of community-acquired pneumonia, especially in adults. Invasive pneumococcal disease can usually occur in the elderly, children and immunocompromised individuals. Usage of the vaccines for the protection against S.pneumoniae infections, is an effective method to reduce the burden of disease in both children and adults. Serotypes frequently isolated from purified capsular polysaccharides of S...
July 2017: Mikrobiyoloji Bülteni
https://www.readbyqxmd.com/read/28922566/streptococcus-pneumoniae-and-chronic-endobronchial-infections-in-childhood
#16
Kim M Hare, Amanda J Leach, Heidi C Smith-Vaughan, Anne B Chang, Keith Grimwood
Streptococcus pneumoniae (pneumococcus) is the main cause of bacterial pneumonia worldwide and has been studied extensively in this context. However, its role in chronic endobronchial infections and accompanying lower airway neutrophilic infiltration has received little attention. Severe and recurrent pneumonia are risk factors for chronic suppurative lung disease (CSLD) and bronchiectasis; the latter causes considerable morbidity and, in some populations, premature death in children and adults. Protracted bacterial bronchitis (PBB) is another chronic endobronchial infection associated with substantial morbidity...
September 18, 2017: Pediatric Pulmonology
https://www.readbyqxmd.com/read/28911953/associations-between-complementary-medicine-utilization-and-influenza-pneumococcal-vaccination-results-of-a-national-cross-sectional-survey-of-9151-australian-women
#17
Jon Wardle, Jane Frawley, Jon Adams, David Sibbritt, Amie Steel, Romy Lauche
Influenza and pneumococcal vaccination is recommended for all adults, with older adults considered a high-risk group for targeted intervention. As such it is important for factors affecting vaccine uptake in this group to be examined. Complementary medicine (CM) use has been suggested as a possible factor associated with lower vaccination uptake. To determine if associations exist between influenza and pneumococcal vaccine uptake in older Australian women and the use of CM, data from women aged 62-67years surveyed as part of the Australian Longitudinal Study on Women's Health (ALSWH) were analyzed in 2013 regarding their health and health care utilization...
September 12, 2017: Preventive Medicine
https://www.readbyqxmd.com/read/28910279/longitudinal-multiparameter-single-cell-analysis-of-macaques-immunized-with-pneumococcal-protein-conjugated-or-unconjugated-polysaccharide-vaccines-reveals-distinct-antigen-specific-memory-b-cell-repertoires
#18
Bin Jia, Lisa K McNeil, Christopher D Dupont, Konstantinos Tsioris, Rachel M Barry, Ingrid L Scully, Adebola O Ogunniyi, Christopher Gonzalez, Michael W Pride, Todd M Gierahn, Paul A Liberator, Kathrin U Jansen, J Christopher Love
BACKGROUND: The efficacy of protein-conjugated pneumococcal polysaccharide vaccines has been well characterized for children. The level of protection conferred by unconjugated polysaccharide vaccines remains less clear, particularly for elderly individuals who have had prior antigenic experience through immunization with unconjugated polysaccharide vaccines or natural exposure to Streptococcus pneumoniae. METHODS: We compared the magnitude, diversity and genetic biases of antigen-specific memory B cells in two groups of adult cynomolgus macaques that were immunized with a 7-valent conjugated vaccine and boosted after five years with either a 13-valent pneumococcal polysaccharide conjugate vaccine (13vPnC) or a 23-valent unconjugated pneumococcal polysaccharide vaccine (23vPS) using microengraving (a single-cell analysis method) and single-cell RT-PCR...
2017: PloS One
https://www.readbyqxmd.com/read/28881165/safety-and-immunogenicity-of-a-13-valent-pneumococcal-conjugate-vaccine-in-adults-50-to-65%C3%A2-years-of-age-in-india-an-open-label-trial
#19
Bhagirath B Solanki, Christine Juergens, Manojkumar B Chopada, Pravin Supe, Vani Sundaraiyer, Natacha Le Dren-Narayanin, Mark W Cutler, William C Gruber, Daniel A Scott, Beate Schmoele-Thoma
Streptococcus pneumoniae infection is a major global public health concern in older adults, especially as life expectancy continues to increase in most countries, including India. Recently, a 13-valent pneumococcal conjugate vaccine (PCV13) with the ability to enhance immunity (immunologic memory) on natural exposure or revaccination has been shown to protect against community-acquired pneumonia and invasive pneumococcal disease in adults 65 years of age and older. An unconjugated 23-valent pneumococcal polysaccharide vaccine has been available for decades; however, data on protection against pneumonia are inconsistent...
September 2, 2017: Human Vaccines & Immunotherapeutics
https://www.readbyqxmd.com/read/28863866/rethinking-number-needed-to-vaccinate-for-pneumococcal-conjugate-vaccines-in-older-adults-current-and-future-implications
#20
John M McLaughlin, David L Swerdlow, Raul E Isturiz, Luis Jodar
BACKGROUND: Number-needed-to-vaccinate (NNV) is increasingly used to inform decisions about vaccine use, but it is not calculated uniformly across studies. This study compared two methodologies for calculating NNV with 13-valent pneumococcal conjugate vaccine (PCV13) to prevent one case of community-acquired pneumonia (CAP) among US adults aged ≥65years: (i) using one-year absolute rate differences as was originally performed by the Centers for Disease Control and Prevention (CDC) and (ii) using absolute risk reduction over 5years...
September 25, 2017: Vaccine
keyword
keyword
57998
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"